Search by Drug Name or NDC
NDC 00085-1430-04 TEMODAR 180 mg/1 Details
TEMODAR 180 mg/1
TEMODAR is a ORAL CAPSULE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Merck Sharp & Dohme LLC. The primary component is TEMOZOLOMIDE.
MedlinePlus Drug Summary
Temozolomide is used to treat certain types of brain tumors. Temozolomide is in a class of medications called alkylating agents. It works by slowing or stopping the growth of cancer cells in your body.
Related Packages: 00085-1430-04Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Temozolomide
Product Information
| NDC | 00085-1430 |
|---|---|
| Product ID | 0085-1430_377e34ef-4f0a-4edc-8353-a9967683b580 |
| Associated GPIs | 21104070000147 |
| GCN Sequence Number | 062536 |
| GCN Sequence Number Description | temozolomide CAPSULE 180 MG ORAL |
| HIC3 | V1A |
| HIC3 Description | ANTINEOPLASTIC - ALKYLATING AGENTS |
| GCN | 98311 |
| HICL Sequence Number | 020355 |
| HICL Sequence Number Description | TEMOZOLOMIDE |
| Brand/Generic | Brand |
| Proprietary Name | TEMODAR |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Temozolomide |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | CAPSULE |
| Route | ORAL |
| Active Ingredient Strength | 180 |
| Active Ingredient Units | mg/1 |
| Substance Name | TEMOZOLOMIDE |
| Labeler Name | Merck Sharp & Dohme LLC |
| Pharmaceutical Class | Alkylating Activity [MoA], Alkylating Drug [EPC] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA021029 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00085-1430-04 (00085143004)
| NDC Package Code | 0085-1430-04 |
|---|---|
| Billing NDC | 00085143004 |
| Package | 14 PACKET in 1 CARTON (0085-1430-04) / 1 CAPSULE in 1 PACKET (0085-1430-05) |
| Marketing Start Date | 1999-08-11 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |